Clinical Trial: A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07753824) titled 'A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)' on Aug. 03.

Brief Summary: To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).

Study Start Date: Jan. 16, 2027

Study Type: INTERVENTIONAL

Condition: Phase II Ivonescimab Intraperitoneal Paclitaxel High Grade Metastatic Appendiceal Adenocarcinoma

Intervention: DRUG: Ivonescimab

Given by IV

DRUG: IP PTX

Given by IP port

Recruitment Status: NOT_YE...